Key result
Platelet GPVI emerges as a potent antithrombotic target for future cardiovascular therapies.
Why the study?
Platelet glycoprotein VI has recently been identified as a potent antithrombotic target in thrombosis caused by acute coronary syndrome and stroke.
Platelet glycoprotein VI (GPVI) is highlighted as a potent and promising novel target for antithrombotic therapy in cardiovascular diseases like acute coronary syndrome and stroke.
Should not yet change antiplatelet practice; leaves open GPVI as a target pending randomized trials.
Platelets play an important role in thrombosis caused by acute coronary syndrome and stroke. As the main platelet collagen receptor, platelet glycoprotein Ⅵ (GPⅥ) is an important modulator in the activation and aggregation of platelets at vascular injury sites. Recently, GPⅥ has been identified as a potent antithrombotic target. The structure, properties, functions, and downstream signaling of GPⅥ are reviewed; its relationship with bleeding, thrombosis, and other diseases are discussed; and potential of GPⅥ as a future antiplatelet therapeutic target is summarized in this article.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2024) conducted a review in Cardiovascular disease and thrombosis. Platelet Glycoprotein VI (GPVI) targeted therapy was evaluated. Platelet glycoprotein VI (GPVI) is highlighted as a potent antithrombotic target with significant potential as a future antiplatelet therapy for cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: